A hungry Takeda continues deal spree with $125M T cell pact, option to buy
Takeda is on a tear.
Two days after announcing a $5.2 billion deal to acquire Ariad, the global Japanese pharma company is back with the latest in a string of smaller pacts, investing $125 million in Maverick Therapeutics and picking up an option to buy the biotech and its T cell engagement platform.
The cash comes for an upfront payment, equity stake and R&D support, with Takeda stepping into a $23 million Series B to help fuel the next round of development. Takeda and Maverick, an MPM Capital company, have already worked out a buyout price for five years down the road, but they aren’t disclosing it.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.